FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

NewsGuard 100/100 Score
May 15 2010

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Cinacalcet HCl Tablets 30, 60 & 90 mg.

Upon final approval, Teva's Cinacalcet HCl Tablets will be the AB-rated generic equivalent of Amgen's Sensipar®, indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

The brand product had annual sales of approximately $458 million in the United States, based on IMS sales data.

Teva is currently involved in patent litigation concerning this product in the U.S. District Court for the District of Delaware. A trial date has not been set.

SOURCE Teva Pharmaceutical Industries Ltd.,

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Ultra-processed foods raise chronic kidney disease risk, study shows
Food allergies' broad impact on quality of life demands greater awareness
How can food influence the severity of menopausal hot flashes?
Omalizumab boosts tolerance to multiple food allergies, study finds
Renaissance of "food as medicine" in modern clinical trials
Maternal influences on food allergy prevention: A closer look at diet and environment
Study links ultra-processed food consumption with higher cardiovascular risk
Study reveals daily food environment exposure shapes fast food habits

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings